表紙:炭疽病 (感染症):開発中の薬剤、2021年
市場調査レポート
商品コード
1000854

炭疽病 (感染症):開発中の薬剤、2021年

Anthrax (Infectious Disease) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 124 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
炭疽病 (感染症):開発中の薬剤、2021年
出版日: 2021年03月31日
発行: Global Markets Direct
ページ情報: 英文 124 Pages
納期: 即納可能 即納可能とは
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

炭疽病は、炭疽菌によって引き起こされる深刻な感染症です。主な兆候・症状として、吐き気、嘔吐、腹痛、頭痛、食欲不振、発熱、(疾患の後期段階での) 重度の血性下痢、喉の痛み、嚥下困難などが含まれています。リスク要因には、違法薬物の注射、動物の皮膚の取り扱い、獣医学関連の業務 (特に家畜の取り扱い) などが含まれています。

当レポートでは、世界各国での炭疽病の治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

  • イントロダクション
  • 炭疽病:概要
  • 炭疽病:治療薬の開発
  • 炭疽病:治療薬の評価
  • 炭疽病:治療薬の開発に従事している企業
  • 炭疽病:薬剤プロファイル
  • 炭疽病:開発が休止状態の製品
  • 炭疽病:開発が中止された製品
  • 炭疽病:製品開発のマイルストーン
  • 付録
図表

List of Tables

  • Number of Products under Development for Anthrax, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Anthrax - Pipeline by Altimmune Inc, 2021
  • Anthrax - Pipeline by Aphios Corp, 2021
  • Anthrax - Pipeline by Aradigm Corp (Inactive), 2021
  • Anthrax - Pipeline by Biologics Resources LLC, 2021
  • Anthrax - Pipeline by BlueWillow Biologics Inc, 2021
  • Anthrax - Pipeline by China Biologic Products Holdings Inc, 2021
  • Anthrax - Pipeline by Crestone Inc, 2021
  • Anthrax - Pipeline by Dynavax Technologies Corp, 2021
  • Anthrax - Pipeline by Emergent BioSolutions Inc, 2021
  • Anthrax - Pipeline by GC Pharma, 2021
  • Anthrax - Pipeline by Greffex Inc, 2021
  • Anthrax - Pipeline by Hawaii Biotech Inc, 2021
  • Anthrax - Pipeline by iBio Inc, 2021
  • Anthrax - Pipeline by Innovative Biologics Inc, 2021
  • Anthrax - Pipeline by Integrated BioTherapeutics Inc, 2021
  • Anthrax - Pipeline by iNtRON Biotechnology Inc, 2021
  • Anthrax - Pipeline by Opal Biosciences Ltd, 2021
  • Anthrax - Pipeline by Paratek Pharmaceuticals Inc, 2021
  • Anthrax - Pipeline by Protein Potential LLC, 2021
  • Anthrax - Pipeline by ProThera Biologics Inc, 2021
  • Anthrax - Pipeline by Soligenix Inc, 2021
  • Anthrax - Pipeline by Vast Therapeutics Inc, 2021
  • Anthrax - Pipeline by Venomyx Inc, 2021
  • Anthrax - Pipeline by VLP Biotech Inc, 2021
  • Anthrax - Dormant Projects, 2021
  • Anthrax - Dormant Projects, 2021 (Contd..1)
  • Anthrax - Dormant Projects, 2021 (Contd..2)
  • Anthrax - Dormant Projects, 2021 (Contd..3)
  • Anthrax - Discontinued Products, 2021

List of Figures

  • Number of Products under Development for Anthrax, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
目次
Product Code: GMDHC12801IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Drugs in Development, 2021, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Anthrax - Overview
  • Anthrax - Therapeutics Development
  • Anthrax - Therapeutics Assessment
  • Anthrax - Companies Involved in Therapeutics Development
  • Anthrax - Drug Profiles
  • Anthrax - Dormant Projects
  • Anthrax - Discontinued Products
  • Anthrax - Product Development Milestones
  • Appendix